Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure.
about
Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionEvaluation and management of patients with heart disease and cancer: cardio-oncologyErbB2 signaling at the crossing between heart failure and cancerDirect binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signalingActivation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Mouse models of gene-environment interactions in schizophrenia.Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Affecting Rhomboid-3 function causes a dilated heart in adult Drosophila.Novel biomarkers for cardiovascular risk prediction.And the beat goes on: maintained cardiovascular function during aging in the longest-lived rodent, the naked mole-rat.Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.Cardiovascular toxicities from systemic breast cancer therapy.The effects of neuregulin on cardiac Myosin light chain kinase gene-ablated heartsRecombinant neuregulin 1 does not activate cardiomyocyte DNA synthesis in normal or infarcted adult mice.Improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: differential expression of microRNA.Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats.Neuregulin-1β for the treatment of systolic heart failure.Associations of Sleep Apnea, NRG1 Polymorphisms, Alcohol Consumption, and Cerebral White Matter Hyperintensities: Analysis with Genome-Wide Association Data.Breast cancer therapy and cardiovascular risk: focus on trastuzumabCirculating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia.Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled TrialImprovement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure.The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload.Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction.The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular riskTowards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic CardiomyopathyA recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyCardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?The role of Neuregulin-1beta/ErbB signaling in the heart.Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure.Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lungProtein therapeutics for cardiac regeneration after myocardial infarction.
P2860
Q26853363-7B9598ED-6522-43C7-980D-4EBDC0BF3BDFQ26998273-F89E12C0-3C28-4727-ABBF-205DF5758958Q28075244-BA31C75D-5CA1-495D-9B68-E360CDE88E91Q28116711-4931D15E-E7A5-4134-94EF-00778327D5BDQ29347286-A4417822-DB5E-45E4-8DC7-06AA254A6586Q30402943-49878F71-80B8-4FD5-9E26-BC72A8FD8EE5Q30432026-B6BFA2F6-D32C-4E91-9BEB-09367AF5BF21Q30593372-2A7DB89C-C62A-4B15-93A6-DE3071C1EB18Q33594430-08BAE620-0CD0-448C-A158-878C5613E6AEQ33615459-F474F686-CF46-46E8-AAF6-93491139C7F4Q34001736-6C014AB4-C69C-433E-B261-BD9F58F60AB1Q34062716-8798D367-F0EA-4367-94EB-4653CD351CF3Q34630349-2E4E261C-4072-4E7C-B7EF-6EF13B32E7DDQ34776866-99E0A4CF-372D-4F11-80EA-4D6A2AA6F35AQ34784347-38B904B1-3766-4238-8706-EB4E53A336B4Q35086774-E0304AEF-8754-4F97-8ED7-8EA87BC27A69Q35207833-AE7D29E1-43EC-44CD-8828-3C2D1688778FQ35231868-F7DD5E40-2375-4374-9AEA-D09E22F36402Q35343873-90DDC5C4-41B7-45EF-A4D9-263CF58EC39EQ35427876-4765B1CC-9A7C-43D5-ABD7-4B67F18EE02FQ35552999-172F1534-3A4F-40EF-8A89-23E71DF75175Q35935011-AC8AF84B-944C-40CF-AD9A-B4D44CAF080CQ36038613-0220A0DC-E11D-4232-BADD-451D9E7F8222Q36163718-F7AD86AF-545F-4F98-8E45-196BC73B6FA2Q36227198-6D1D9B05-50DB-4594-89AD-B4F19B1110BEQ36346991-6638A592-391D-415B-9D9F-73123531BE6AQ36630478-D9E08587-6847-4D9B-A455-1F41F8C0EBF9Q36637796-516E0C67-9EEF-408B-8C8D-32C8702425E8Q36755620-0E234E17-66F0-40A0-8FFE-C7F3C0229F81Q36775652-52D99746-AA2B-4E19-A061-65184682814EQ36915712-B52F3BB4-965E-49FA-B7F6-EED2FAAE001FQ36930808-AB52E8F2-5621-4BB3-8744-DA976E4D6991Q37052852-16F1A22F-56D7-408F-B51A-B45E2C620E70Q37076096-FAFDA3AF-4BBE-494D-9E7B-7A8ABC9C9BA5Q37131070-B5A05A74-FD4A-4C5A-BF66-E255D45C37D1Q37155921-C8AD94A2-B2FF-42E4-ADA8-D46725493F2DQ37288691-756C3072-4FEE-4536-80BE-DBC19A192214Q37341103-3BCBC822-9912-4CE6-9408-2CDF64AB1CB4Q37688390-3275B8D7-6BF4-4AB2-9AB2-1F5332E4C23DQ37770453-FC854691-4A26-4358-9964-AACAFDC79F8F
P2860
Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of neuregulin-1/ErbB sign ...... for therapy of heart failure.
@en
type
label
Role of neuregulin-1/ErbB sign ...... for therapy of heart failure.
@en
prefLabel
Role of neuregulin-1/ErbB sign ...... for therapy of heart failure.
@en
P1433
P1476
Role of neuregulin-1/ErbB sign ...... for therapy of heart failure.
@en
P2093
Katrien Lemmens
Kris Doggen
P304
P356
10.1161/CIRCULATIONAHA.107.690487
P407
P577
2007-08-01T00:00:00Z